

Pembrolizumab Solid Formulation

Version 4.1 Revision Date: 30.09.2023 SDS Number: 525403-00018 Date of last issue: 04.04.2023
Date of first issue: 23.02.2016

SECTION 1: Identification of the substance/mixture and of the company/undertaking**1.1 Product identifier**

Trade name : Pembrolizumab Solid Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-stance/Mixture : Pharmaceutical

Recommended restrictions on use : Not applicable

1.3 Details of the supplier of the safety data sheet

Company : MSD
117 16th Road
1685 Halfway house, Midrand, South Africa

Telephone : +27 11 655 3000

E-mail address of person responsible for the SDS : EHSDATASTEWARD@msd.com


1.4 Emergency telephone number

+1-908-423-6000

SECTION 2: Hazards identification**2.1 Classification of the substance or mixture****Classification (REGULATION (EC) No 1272/2008)**

Reproductive toxicity, Category 1B H360D: May damage the unborn child.
Specific target organ toxicity - repeated exposure, Category 1 H372: Causes damage to organs through prolonged or repeated exposure.

2.2 Label elements**Labelling (REGULATION (EC) No 1272/2008)**

Hazard pictograms : 

Signal word : Danger

Hazard statements : H360D May damage the unborn child.
H372 Causes damage to organs through prolonged or repeated exposure.

Pembrolizumab Solid Formulation

Version 4.1 Revision Date: 30.09.2023 SDS Number: 525403-00018 Date of last issue: 04.04.2023
 Date of first issue: 23.02.2016

Precautionary statements : **Prevention:**
 P201 Obtain special instructions before use.
 P260 Do not breathe dust.
 P264 Wash skin thoroughly after handling.
 P270 Do not eat, drink or smoke when using this product.
 P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:
 P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Hazardous components which must be listed on the label:
 Pembrolizumab

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

| Chemical name | CAS-No. EC-No. Index-No. Registration number | Classification | Concentration (% w/w) |
|---------------|---|---|--------------------------|
| Pembrolizumab | 1374853-91-4 | Repr. 1B; H360D STOT RE 1; H372 (Immune system) | >= 20 - < 30 |

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
 When symptoms persist or in all cases of doubt seek medical advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled : If inhaled, remove to fresh air.
 Get medical attention.

Pembrolizumab Solid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 04.04.2023 |
| 4.1 | 30.09.2023 | 525403-00018 | Date of first issue: 23.02.2016 |

- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.
- In case of eye contact : If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

- Risks : May damage the unborn child.
Causes damage to organs through prolonged or repeated exposure.
- Contact with dust can cause mechanical irritation or drying of the skin.
Dust contact with the eyes can lead to mechanical irritation.

4.3 Indication of any immediate medical attention and special treatment needed

- Treatment : Treat symptomatically and supportively.
-

SECTION 5: Firefighting measures**5.1 Extinguishing media**

- Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

- Unsuitable extinguishing media : None known.

5.2 Special hazards arising from the substance or mixture

- Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
Exposure to combustion products may be a hazard to health.

- Hazardous combustion products : Carbon oxides
Nitrogen oxides (NO_x)

5.3 Advice for firefighters

- Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

Pembrolizumab Solid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 04.04.2023 |
| 4.1 | 30.09.2023 | 525403-00018 | Date of first issue: 23.02.2016 |

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

SECTION 6: Accidental release measures**6.1 Personal precautions, protective equipment and emergency procedures**

Personal precautions : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage**7.1 Precautions for safe handling**

Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling : Do not get on skin or clothing.
Do not breathe dust.

Pembrolizumab Solid Formulation

Version 4.1 Revision Date: 30.09.2023 SDS Number: 525403-00018 Date of last issue: 04.04.2023
Date of first issue: 23.02.2016

Do not swallow.
Avoid contact with eyes.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers : Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.

Advice on common storage : Do not store with the following product types:
Strong oxidizing agents
Self-reactive substances and mixtures
Organic peroxides
Explosives
Gases

7.3 Specific end use(s)

Specific use(s) : No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

| Components | CAS-No. | Value type (Form of exposure) | Control parameters | Basis |
|---|--------------|-------------------------------|-------------------------------|----------|
| Sucrose | 57-50-1 | OEL-RL | 10 mg/m ³ | ZA OEL |
| Further information: Occupational Exposure Limits - Restricted Limits For Hazardous Chemical Agents | | | | |
| Pembrolizumab | 1374853-91-4 | TWA | 450 µg/m ³ (OEB 2) | Internal |

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

| Substance name | End Use | Exposure routes | Potential health effects | Value |
|----------------|---------|-----------------|----------------------------|-------------------------|
| Histidine | Workers | Inhalation | Long-term systemic effects | 83,38 mg/m ³ |

Pembrolizumab Solid Formulation

Version 4.1 Revision Date: 30.09.2023 SDS Number: 525403-00018 Date of last issue: 04.04.2023
 Date of first issue: 23.02.2016

| | | | | |
|--|-----------|--------------|----------------------------|-------------------------|
| | Workers | Skin contact | Long-term systemic effects | 236,45 mg/kg bw/day |
| | Consumers | Inhalation | Long-term systemic effects | 20,56 mg/m ³ |
| | Consumers | Skin contact | Long-term systemic effects | 118,2 mg/kg bw/day |
| | Consumers | Ingestion | Long-term systemic effects | 11,8 mg/kg bw/day |

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

| Substance name | Environmental Compartment | Value |
|----------------|-----------------------------|-------------------------------|
| Histidine | Fresh water | 0,1 mg/l |
| | Freshwater - intermittent | 1 mg/l |
| | Marine water | 0,01 mg/l |
| | Marine water - intermittent | 1 mg/l |
| | Sewage treatment plant | 20,5 mg/l |
| | Fresh water sediment | 0,392 mg/kg dry weight (d.w.) |
| | Marine sediment | 0,039 mg/kg dry weight (d.w.) |
| | Soil | 0,02 mg/kg dry weight (d.w.) |

8.2 Exposure controls

Engineering measures

Minimize workplace exposure concentrations.

Apply measures to prevent dust explosions.

Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).

If sufficient ventilation is unavailable, use with local exhaust ventilation.

Personal protective equipment

Eye/face protection : Wear the following personal protective equipment:
Safety goggles

Hand protection

Material : Chemical-resistant gloves

Remarks : Choose gloves to protect hands against chemicals depending on the concentration and quantity of the hazardous substance and specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.

Skin and body protection : Select appropriate protective clothing based on chemical resistance data and an assessment of the local exposure potential.
Skin contact must be avoided by using impervious protective clothing (gloves, aprons, boots, etc).

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the rec-

Pembrolizumab Solid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 04.04.2023 |
| 4.1 | 30.09.2023 | 525403-00018 | Date of first issue: 23.02.2016 |

Filter type : Recommended guidelines, use respiratory protection.
: Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

| | | |
|--|---|---|
| Appearance | : | powder |
| Colour | : | white to off-white |
| Odour | : | No data available |
| Odour Threshold | : | No data available |
| pH | : | No data available |
| Melting point/freezing point | : | No data available |
| Initial boiling point and boiling range | : | No data available |
| Flash point | : | Not applicable |
| Evaporation rate | : | No data available |
| Flammability (solid, gas) | : | May form explosive dust-air mixture during processing, handling or other means. |
| Upper explosion limit / Upper flammability limit | : | No data available |
| Lower explosion limit / Lower flammability limit | : | No data available |
| Vapour pressure | : | No data available |
| Relative vapour density | : | No data available |
| Relative density | : | No data available |
| Density | : | No data available |
| Solubility(ies) | | |
| Water solubility | : | No data available |
| Partition coefficient: n-octanol/water | : | No data available |
| Auto-ignition temperature | : | No data available |
| Decomposition temperature | : | No data available |
| Viscosity | | |
| Viscosity, dynamic | : | No data available |
| Viscosity, kinematic | : | No data available |
| Explosive properties | : | Not explosive |
| Oxidizing properties | : | The substance or mixture is not classified as oxidizing. |

Pembrolizumab Solid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 04.04.2023 |
| 4.1 | 30.09.2023 | 525403-00018 | Date of first issue: 23.02.2016 |

9.2 Other information

| | | |
|------------------------|---|-------------------|
| Flammability (liquids) | : | No data available |
| Molecular weight | : | No data available |
| Particle size | : | No data available |

SECTION 10: Stability and reactivity**10.1 Reactivity**

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

| | | |
|---------------------|---|--|
| Hazardous reactions | : | May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents. |
|---------------------|---|--|

10.4 Conditions to avoid

| | | |
|---------------------|---|---|
| Conditions to avoid | : | Heat, flames and sparks. Avoid dust formation. |
|---------------------|---|---|

10.5 Incompatible materials

| | | |
|--------------------|---|------------------|
| Materials to avoid | : | Oxidizing agents |
|--------------------|---|------------------|

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information**11.1 Information on toxicological effects**

| | | |
|--|---|--|
| Information on likely routes of exposure | : | Inhalation Skin contact Ingestion Eye contact |
|--|---|--|

Acute toxicity

Not classified based on available information.

Skin corrosion/irritation

Not classified based on available information.

Serious eye damage/eye irritation

Not classified based on available information.

Pembrolizumab Solid Formulation

Version 4.1 Revision Date: 30.09.2023 SDS Number: 525403-00018 Date of last issue: 04.04.2023
Date of first issue: 23.02.2016

Respiratory or skin sensitisation**Skin sensitisation**

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Germ cell mutagenicity

Not classified based on available information.

Carcinogenicity

Not classified based on available information.

Reproductive toxicity

May damage the unborn child.

Components:**Pembrolizumab:**

Reproductive toxicity - Assessment : May damage the unborn child., Based on data from similar materials

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Causes damage to organs through prolonged or repeated exposure.

Components:**Pembrolizumab:**

Target Organs : Immune system
Assessment : Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Components:****Pembrolizumab:**

Species : Monkey
NOAEL : 200 mg/kg
Application Route : Intravenous
Exposure time : 180 d
Remarks : No significant adverse effects were reported

Species : Dog
NOAEL : 200 mg/kg
Application Route : Intravenous
Exposure time : 180 d
Remarks : No significant adverse effects were reported

Aspiration toxicity

Not classified based on available information.

Pembrolizumab Solid Formulation

Version 4.1 Revision Date: 30.09.2023 SDS Number: 525403-00018 Date of last issue: 04.04.2023
Date of first issue: 23.02.2016

Experience with human exposure

Components:

Pembrolizumab:

Inhalation : Target Organs: Immune system
Symptoms: Cough, Fatigue, Nausea, pruritis, Rash, constipation, joint pain, Diarrhoea, Pneumonia, decrease in appetite, Fever, anemia, neutropenia, musculoskeletal pain, Vomiting, confusion, Headache, Shortness of breath, Hypofunction of thyroid gland, May cause respiratory arrest., May cause, immune-mediated pneumonitis, colitis, hepatitis, nephritis
Remarks: Damage to fetus possible

SECTION 12: Ecological information

12.1 Toxicity

No data available

12.2 Persistence and degradability

No data available

12.3 Bioaccumulative potential

No data available

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment

Product:

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Other adverse effects

Product:

Endocrine disrupting potential : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.

Pembrolizumab Solid Formulation

Version 4.1 Revision Date: 30.09.2023 SDS Number: 525403-00018 Date of last issue: 04.04.2023
Date of first issue: 23.02.2016

Contaminated packaging : Do not dispose of waste into sewer.
: Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information**14.1 UN number**

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

14.2 UN proper shipping name

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

14.3 Transport hazard class(es)

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

14.4 Packing group

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA (Cargo) : Not regulated as a dangerous good
IATA (Passenger) : Not regulated as a dangerous good

14.5 Environmental hazards

Not regulated as a dangerous good

14.6 Special precautions for user

Not applicable

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks : Not applicable for product as supplied.

Pembrolizumab Solid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 04.04.2023 |
| 4.1 | 30.09.2023 | 525403-00018 | Date of first issue: 23.02.2016 |

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

The components of this product are reported in the following inventories:

| | | |
|-------|---|----------------|
| AICS | : | not determined |
| DSL | : | not determined |
| IECSC | : | not determined |

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

| | | |
|-------------------|---|--|
| Other information | : | Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines. |
|-------------------|---|--|

Full text of H-Statements

| | | |
|-------|---|--|
| H360D | : | May damage the unborn child. |
| H372 | : | Causes damage to organs through prolonged or repeated exposure if swallowed. |

Full text of other abbreviations

| | | |
|-----------------|---|--|
| Repr. | : | Reproductive toxicity |
| STOT RE | : | Specific target organ toxicity - repeated exposure |
| ZA OEL | : | South Africa. The Regulations for Hazardous Chemical Agents, Occupational Exposure Limits |
| ZA OEL / OEL-RL | : | Occupational Exposure Limit Restricted limit - 8- hour exposure or equivalent (12 hour shifts) |

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - Interna-

Pembrolizumab Solid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 04.04.2023 |
| 4.1 | 30.09.2023 | 525403-00018 | Date of first issue: 23.02.2016 |

tional Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Classification of the mixture:

| | |
|-----------|-------|
| Repr. 1B | H360D |
| STOT RE 1 | H372 |

Classification procedure:

| |
|--------------------|
| Calculation method |
| Calculation method |

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

ZA / EN